Drug Profile

TTX RIGA

Alternative Names: TTX-RIGA

Latest Information Update: 26 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TransCode Therapeutics
Class Antineoplastics; Antisense oligonucleotides
Mechanism of Action DDX58 protein stimulants; DEAD-box RNA helicase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Malignant melanoma

Most Recent Events

20 Feb 2024 TransCode Therapeutics has a patent pending for immunotherapy targeting molecules called retinoic acid-inducible gene I (RIG-I)-like receptors in USA
17 Oct 2023 Pharmacodynamics data from a preclinical study in Malignant melanoma released by TransCode Therapeutics
17 Oct 2023 TransCode Therapeutics plans a clinical trial for malignant melanoma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com